Ghassan K. Abou-Alfa
加桑·阿布-阿尔法
MD, MBA
Attending Physician, Gastrointestinal Oncology Service胃肠肿瘤科主治医师
👥Biography 个人简介
Ghassan K. Abou-Alfa, MD is a leading GI oncologist at MSK and international authority on hepatobiliary malignancies. He is best known for leading the ClarIDHy trial of ivosidenib in IDH1-mutated cholangiocarcinoma and contributing to pivotal trials across biliary tract and liver cancers, profoundly shaping global standards of care.
🧪Research Fields 研究领域
🎓Key Contributions 主要贡献
ClarIDHy Trial — Ivosidenib in IDH1-Mutated Cholangiocarcinoma
Led the phase III ClarIDHy trial showing ivosidenib improved progression-free survival vs placebo in previously treated IDH1-mutated cholangiocarcinoma, supporting FDA approval of ivosidenib in this indication.
Global GI Oncology Drug Development
Contributed to landmark trials of sorafenib (SHARP), cabozantinib, and ramucirumab in HCC alongside major biliary tract cancer studies, establishing an unparalleled cross-hepatobiliary clinical trial portfolio.
Representative Works 代表性著作
Ivosidenib in IDH1-mutant, chemotherapy-refractory cholangiocarcinoma (ClarIDHy): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study
The Lancet Oncology (2020)
Phase III trial demonstrating ivosidenib improved PFS in IDH1-mutated cholangiocarcinoma, leading to FDA approval of the first IDH1-directed therapy in biliary tract cancer.
🏆Awards & Recognition 奖项与荣誉
📄Data Sources 数据来源
Last updated: 2026-01-15 | All information from publicly available academic sources
Related Experts 相关专家
Antoni Ribas
UCLA Jonsson Comprehensive Cancer Center
Drew M. Pardoll
Johns Hopkins University
Padmanee Sharma
MD Anderson Cancer Center
Naiyer A. Rizvi
Columbia University Irving Medical Center
关注 加桑·阿布-阿尔法 的研究动态
Follow Ghassan K. Abou-Alfa's research updates
留下邮箱，当我们发布与 Ghassan K. Abou-Alfa（Memorial Sloan Kettering Cancer Center）相关的新研究或访谈时，我们会通知你。
Explore More Experts
Discover the researchers shaping the future of cancer treatment